20 March, 2019
Tetraneuron, resident company of Johnson & Johnson Innovation – JLABS Tetraneuron, a spin-off of Jose M. Frade’s lab at the Cajal Institute, is a resident company […]
30 November, 2018
Participation in the XVII edition of the Farma-Biotech Program Different Spanish biotechnology companies and research groups, including Tetraneuron, presented on Wednesday, November, 28, 2018, a total […]
10 October, 2018
Therapy: Publication of the European patent grant. On September 5, 2018, the European Patent Office granted the patent for our therapy with No. EP2783696 “Phosphorylation on the Thr-248 […]
28 September, 2018
Presenting company in BIOSPAIN 2018 Tetraneuron was selected to make a company presentation during the BIOSPAIN Congress that took place in Seville in September 25-27, 2018 […]
17 October, 2017
Biomarker: Publication of the Spanish patent grant. On October 9, 2017, the Spanish Patent and Trademark Office granted the patent for our biomarker with No. ES2598885 ” Method […]
29 September, 2017
Tetraneuron in ASEBIO Investor Day 2017 Tetraneuron was one of the 30 Spanish biotech start-ups selected to present their project at ASEBIO Investor Day, on September 26-27, […]
20 July, 2017
Tetraneuron presents its Poster at AAIC17 Last Monday, July 17th José María Frade, Tetraneuron’s Scientific Director, presented at AAIC17 his Poster: “A Mutant Form of E2F4 […]
25 May, 2017
Therapy: Publication of the Japan patent grant. On March 22, 2017, the Japanese Patent Office granted the patent for our therapy with No. 6100276 “Phosphorylation on the Thr-248 […]
12 May, 2017
Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology The study has recently been accepted and published […]
13 March, 2017
Therapy: Publication of the US patent grant. On February 14, 2017, the United States Patent and Trademark Office granted the patent for our therapy with No. 9,567,384 […]